- The company has simplified the testing of PAD, which is a marker for increased risk of stroke and cardiovascular disease.
- It runs on a capital light, license fee business model that generates high margins and substantial cash flows.
- The pandemic has interrupted the progress, but the company seems well placed to weather the storm.
Semler Scientific: A Little Gem Of A Company
June 30th, 2020 · No Comments